Navigation Links
Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
Date:3/5/2013

SEATTLE, March 5, 2013 /PRNewswire/ -- Presage Biosciences, a leader in discovering effective cancer drug combinations, today announced that it has entered into a strategic collaboration agreement with Celgene Corporation under which Presage and Celgene will take advantage of Presage's proprietary technology platform to identify novel drug combinations for solid tumor indications.

(Logo: http://photos.prnewswire.com/prnh/20130305/SF70691LOGO)

The Presage platform is the only technology that allows for the direct comparison of multiple drugs or drug combinations in the same living tumor. In addition to identifying combination treatments for cancer, the company ultimately intends to utilize its platform to precisely evaluate patients' unique responses to microdoses of multiple cancer drugs.

Under the terms of the agreement, Presage will receive an upfront payment, an equity investment, and will be eligible for downstream payments.

"Drug development is currently challenged by heavy reliance on in vitro test systems and animal xenografts of little relevance to individual patients," said Thomas Daniel , M.D. Celgene President, Research and Early Development. "The Presage platform addresses this challenge, permitting rapid assessment of drug candidates and combinations in relevant models, with potential to base critical drug development decisions on in vivo response data."

"Celgene is an ideal strategic partner for Presage. The two companies are well aligned in focusing on original approaches to cancer drug discovery," said Nathan Caffo , President of Presage Biosciences. "The innovative structure of this research collaboration will enable us to continue our plan to expand the application of the Presage platform, which offers fundamental insights into novel cancer drug combinations and drug effects in living tumors."

About the Presage Platform
Presage Biosciences' patented drug array platform offers an unprecedented method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single living tumor. The Presage drug array platform enables the precise placement of multiple microdoses of candidate treatments through the skin and directly into a tumor.  Such a controlled localization enables drug-specific responses to be measured within an array of multiple drugs. These three dimensionally delivered microdoses also provide the ability to analyze drug effects across the span of a living tumor while capturing the heterogeneity of cancer cells.

About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

About Presage Biosciences
Presage Biosciences is driving discovery of effective drug combinations. The company is dedicated to improving cancer drug development so that patients can receive the most effective treatment possible.  Presage partners with oncology-focused pharmaceutical companies through strategic alliances to provide previously inaccessible in vivo data to validate novel targets, promote drug candidates to the right indications, and discover effective drug combinations.  Presage has developed the world's only known technology to perform simultaneous comparisons of multiple drugs within a living tumor. Presage is privately held and based in Seattle. For more information, visit www.presagebio.com.


'/>"/>
SOURCE Presage Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Australia Ophthalmic Lasers Market Outlook ... Ophthalmic Lasers Market Outlook to 2022", provides key market ... provides value, in millions of US dollars, volume (in ... Excimer Lasers, Femtosecond Lasers and YAG Lasers. The ... for each of these market segements, and global corporate-level ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has announced the ... to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies in ... Canada , Japan , Europe , ... of World. Annual estimates and forecasts are provided for the period ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle ... in Jefferson County, is announcing the launch of a charity drive to raise ... of homeless women and children in Birmingham has grown steadily since the 1980’s, ...
(Date:12/8/2016)... ... 08, 2016 , ... The Compretta Insurance Agency, a family owned insurance and ... the Hancock County area, is announcing the launch of a charity effort aimed at ... County Food Pantry has worked for more than 30 years to meet the food ...
(Date:12/7/2016)... OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... clinical trials with the announcement that it is one of the early adopters completing ... Privacy Shield Framework is designed to provide companies on both sides of the Atlantic ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry leader ... through a new partnership with Splashtop Inc. This remote control for Android extends ... help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise mobility ...
Breaking Medicine News(10 mins):